RankAlpha logo
Back to Rankings

TEVA

Teva Pharmaceutical IndustriesA
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Q1 showed 41% local-currency growth across AUSTEDO, AJOVY, and UZEDY, biosimilars are becoming a more meaningful contributor, and Emalex plus olanzapine LAI add dated growth hooks if approvals and launches stay on track.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.0.
What can break
Emalex adds cash deployment, integration work, and near-term margin dilution even if the strategic fit is good.
Momentum
81
Value
64
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $40.00 · Bull $46.00 · Bear $29.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $39.78
Why
Momentum81 · Δ7d -5.0
Value64 · Δ7d +0.3
Sentiment66 · Δ7d +2.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
81
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.0
Δ21d
-7.5
Value
64
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.7
Sentiment
66
33% active weight
Current posture
7d trendImproving
Δ7d
+2.0
Δ21d
+17.8
Why this grade

Composite grade A. Momentum 81.2 / Value 63.5 / Sentiment 66.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$40.23B
Beta
0.84
Shares Out
1.15B
P/E (TTM)
49.7
P/S (TTM)
2.08
P/FCF (TTM)
60.34
Rev YoY
+3.4%
EPS YoY
+196.4%
Gross Margin
+51.3%
Op Margin
+10.9%
Net Debt
$14.48B
Current Ratio
1.11
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology